Prasad Kopparapu - Concepedia

Author

Prasad Kopparapu

Oregon State University ORCID

Also Known As

P Kopparapu, P R Kopparapu, Prasad Kopparapu, Prasad R. Kopparapu, Prasad Rao Kopparapu, Prasad Rao Kopparapu (315795)

Publications

568

Citations

H-Index

Concepts

All Affiliations

Oregon State University Vanderbilt University Medical Center Sanford Burnham Prebys Medical Discovery Institute Discovery Institute Vanderbilt University

About

Prasad Kopparapu is an author at Oregon State University specializing in medicine, tumor biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	224
2	Engineering	1	1	87
3	Health Sciences	1	1	45
4	Cell Biology	1	1	78
5	Immunology	1	1	14

Prasad Kopparapu

Publications

515

Citations

H-Index

Page 1

	Year	Citations
The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor Edmond F. O’Donnell, Katerine S. Saili, Daniel C. Koch, PLoS ONE	2010	121
Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes Simon Heeke, Carl M. Gay, Marcos R. Estecio, Cancer Cell Cfdna ClassifierEngineeringEpigenetic ChangeDna MethylationPathology	2024	87
The Aryl Hydrocarbon Receptor Mediates Leflunomide-Induced Growth Inhibition of Melanoma Cells Edmond F. O’Donnell, Prasad Kopparapu, Daniel C. Koch, PLoS ONE Cancer ResearchOncogenic AgentMedicineAryl Hydrocarbon ReceptorInhibitor Leflunomide	2012	78
Benzimidazoisoquinolines: A New Class of Rapidly Metabolized Aryl Hydrocarbon Receptor (AhR) Ligands that Induce AhR-Dependent Tregs and Prevent Murine Graft-Versus-Host Disease Sumit Punj, Prasad Kopparapu, Hyo Sang Jang, PLoS ONE	2014	49
Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-β1 Daniel C. Koch, Hyo Sang Jang, Edmond F. O’Donnell, Oncogene Tumor BiologyGrowth Factor-β1Anti-androgen FlutamideLiver PhysiologyAryl Hydrocarbon Receptor	2015	45
Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells Martin C. Pearce, John Gamble, Prasad Kopparapu, Oncotarget	2018	42
Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC Portia Thomas, Sarah M. Groves, Yun-Kai Zhang, Journal of Thoracic Oncology	2021	31
Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease Wade T. Iams, Prasad Kopparapu, Yingjun Yan, JTO Clinical and Research Reports	2020	22
Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC Jarrod T. Smith, Aneri Balar, Dhairya A. Lakhani, JTO Clinical and Research Reports	2020	16
Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer Christine M. Lovly, Kelli L. Boyd, Paula I. González-Ericsson, Acute Lung InjuryAdvanced Lung DiseaseLung InflammationRespiratory DiseasesImmune Checkpoint Inhibitors	2020	14

Page 1